Research Progress of Aromatic Bed Curtains for Aiding Sleep Based on Lavender Microcapsule Technique

In this paper, the preparation technique of lavender essential oil microcapsules and the construction method of aromatic textiles were expounded, and the research status of bed curtains and lavender microcapsules at home and abroad was analyzed and studied from the perspective of application in textiles. The application of lavender essential oil to bed curtains through the microcapsule technique was put forward to allow lavender essential oil to play its role of helping sleep in bed curtains. This paper expounded the material selection and preparation technique of lavender microcapsule agents, and put forward the preparation method of microcapsules with mixed solutions of pure Chinese medicine extracts and natural essences as core material and high-viscosity epoxy resin as wall materials. The post-processing techniques and the spray ironing method for clothing were studied and developed, and these techniques and methods were applied to bed curtains, and good results were obtained.

Safety and efficacy of thalidomide in patients with transfusiondependentβ-thalassemia:a randomized clinical trial

Thalidomide inducesγ-globin expression in erythroid progenitor cells,but its efficacy on patients with transfusion-dependentβ-thalassemia(TDT)remains unclear.In this phase 2,multi-center,randomized,double-blind clinical trial,we aimed to determine the safety and efficacy of thalidomide in TDT patients.A hundred patients of 14 years or older were randomly assigned to receive placebo or thalidomide for 12 weeks,followed by an extension phase of at least 36 weeks.The primary endpoint was the change of hemoglobin(Hb)level in the patients.The secondary endpoints included the red blood cell(RBC)units transfused and adverse effects.In the placebo-controlled period,Hb concentrations in patients treated with thalidomide achieved a median elevation of 14.0(range,2.5 to 37.5)g/L,whereas Hb in patients treated with placebo did not significantly change.Within the 12 weeks,the mean RBC transfusion volume for patients treated with thalidomide and placebo was 5.4±5.0 U and 10.3±6.4 U,respectively(P<0.001).Adverse events of drowsiness,dizziness,fatigue,pyrexia,sore throat,and rash were more common with thalidomide than placebo.In the extension phase,treatment with thalidomide for 24 weeks resulted in a sustainable increase in Hb concentrations which reached 104.9±19.0 g/L,without blood transfusion.Significant increase in Hb concentration and reduction in RBC transfusions were associated with nonβ0/β0 and HBS1L-MYB(rs9399137 C/T,C/C;rs4895441 A/G,G/G)genotypes.These results demonstrated that thalidomide is effective in patients with TDT.